Suven Pharmaceuticals Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1104.00 +48.45 (4.59%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1046
Today’s High
1146.15
52 Week Low
586.10
52 Week High
1359
1128.15 +73.40 (6.96%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1053.65
Today’s High
1147.10
52 Week Low
585.20
52 Week High
1360
Key Metrics
- Market Cap (In Cr) 26421.3
- Beta 1.73
- Div. Yield (%) 0
- P/B 12.88
- TTM P/E 122.75
- Peg Ratio -17.93
- Sector P/E 28.24
- D/E 0
- Open Price 1046
- Prev Close 1055.55
Suven Pharmaceuticals Analysis
Price Analysis
-
1 Week0.18%
-
3 Months-20.98%
-
6 Month4.81%
-
YTD-8.86%
-
1 Year54.27%
Risk Meter
- 31% Low risk
- 31% Moderate risk
- 31% Balanced Risk
- 31% High risk
- 31% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 0.00
- 0.00
- 0.00
- 0.00
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 1
- 1
- 1
- 1
Suven Pharmaceuticals News
Stocks to Watch: Suven Pharma, Reliance Power, Laurus Labs, Paytm, and more
3 min read . 09 Dec 2024Sunrest Lifescience, MT Educare & others hit 52 week low today ;Check the full list here?
4 min read . 05 Nov 2024Tilaknagar Industries, Aditya Birla Sun Life AMC & others hit 52 week high today ; Do you own any?
3 min read . 05 Nov 2024Suven Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1051.35
- Selling/ General/ Admin Expenses Total
- 159.66
- Depreciation/ Amortization
- 54.5
- Other Operating Expenses Total
- 50
- Total Operating Expense
- 700
- Operating Income
- 351.35
- Net Income Before Taxes
- 405.67
- Net Income
- 300.28
- Diluted Normalized EPS
- 11.89
- Period
- 2024
- Total Assets
- 2254.09
- Total Liabilities
- 203.42
- Total Equity
- 2050.66
- Tangible Book Valueper Share Common Eq
- 78.12
- Period
- 2024
- Cashfrom Operating Activities
- 358.48
- Cashfrom Investing Activities
- -362.25
- Cashfrom Financing Activities
- -13.8
- Net Changein Cash
- -17.57
- Period
- 2023
- Total Revenue
- 1340.33
- Selling/ General/ Admin Expenses Total
- 134.95
- Depreciation/ Amortization
- 47.73
- Other Operating Expenses Total
- 61.91
- Total Operating Expense
- 821.52
- Operating Income
- 518.81
- Net Income Before Taxes
- 559.73
- Net Income
- 411.29
- Diluted Normalized EPS
- 16.16
- Period
- 2023
- Total Assets
- 1965.74
- Total Liabilities
- 230.56
- Total Equity
- 1735.18
- Tangible Book Valueper Share Common Eq
- 65.72
- Period
- 2023
- Cashfrom Operating Activities
- 457.2
- Cashfrom Investing Activities
- -195.01
- Cashfrom Financing Activities
- -241.95
- Net Changein Cash
- 20.24
- Period
- 2022
- Total Revenue
- 1320.22
- Selling/ General/ Admin Expenses Total
- 128.12
- Depreciation/ Amortization
- 39.1
- Other Operating Expenses Total
- 51.84
- Total Operating Expense
- 779.69
- Operating Income
- 540.53
- Net Income Before Taxes
- 667.59
- Net Income
- 453.8
- Diluted Normalized EPS
- 17.83
- Period
- 2022
- Total Assets
- 1829.59
- Total Liabilities
- 302.41
- Total Equity
- 1527.18
- Tangible Book Valueper Share Common Eq
- 59.9
- Period
- 2022
- Cashfrom Operating Activities
- 330
- Cashfrom Investing Activities
- -136.21
- Cashfrom Financing Activities
- -156.41
- Net Changein Cash
- 37.38
- Period
- 2021
- Total Revenue
- 1009.72
- Selling/ General/ Admin Expenses Total
- 102.81
- Depreciation/ Amortization
- 31.64
- Other Operating Expenses Total
- 40.03
- Total Operating Expense
- 600.87
- Operating Income
- 408.84
- Net Income Before Taxes
- 467.67
- Net Income
- 362.34
- Diluted Normalized EPS
- 14.23
- Period
- 2021
- Total Assets
- 1474.47
- Total Liabilities
- 293.66
- Total Equity
- 1180.81
- Tangible Book Valueper Share Common Eq
- 46.28
- Period
- 2021
- Cashfrom Operating Activities
- 382.55
- Cashfrom Investing Activities
- -311.4
- Cashfrom Financing Activities
- -75.66
- Net Changein Cash
- -4.51
- Period
- 2020
- Total Revenue
- 833.79
- Selling/ General/ Admin Expenses Total
- 101.55
- Depreciation/ Amortization
- 23.86
- Other Operating Expenses Total
- 27.43
- Total Operating Expense
- 472.52
- Operating Income
- 361.27
- Net Income Before Taxes
- 404.51
- Net Income
- 317
- Diluted Normalized EPS
- 12.45
- Period
- 2020
- Total Assets
- 1172.81
- Total Liabilities
- 328.05
- Total Equity
- 844.76
- Tangible Book Valueper Share Common Eq
- 33.07
- Period
- 2020
- Cashfrom Operating Activities
- 415.95
- Cashfrom Investing Activities
- -421.53
- Cashfrom Financing Activities
- 6.37
- Net Changein Cash
- 0.79
- Period
- 2019
- Total Revenue
- 377.83
- Selling/ General/ Admin Expenses Total
- 47.75
- Depreciation/ Amortization
- 11.5
- Other Operating Expenses Total
- 13.15
- Total Operating Expense
- 215.09
- Operating Income
- 162.74
- Net Income Before Taxes
- 157.87
- Net Income
- 109.27
- Diluted Normalized EPS
- 4.29
- Period
- 2019
- Total Assets
- 783.02
- Total Liabilities
- 192.73
- Total Equity
- 590.29
- Tangible Book Valueper Share Common Eq
- 23.08
- Period
- 2019
- Cashfrom Operating Activities
- 50.4
- Cashfrom Investing Activities
- -65.48
- Cashfrom Financing Activities
- 25.98
- Net Changein Cash
- 10.9
- Period
- 2024-09-30
- Total Revenue
- 257.72
- Selling/ General/ Admin Expenses Total
- 51.87
- Depreciation/ Amortization
- 16.96
- Other Operating Expenses Total
- 49.78
- Total Operating Expense
- 170.67
- Operating Income
- 87.05
- Net Income Before Taxes
- 99.5
- Net Income
- 82.21
- Diluted Normalized EPS
- 3.21
- Period
- 2024-09-30
- Total Assets
- 2505.56
- Total Liabilities
- 527.22
- Total Equity
- 1978.34
- Tangible Book Valueper Share Common Eq
- 67.05
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 177.67
- Cashfrom Investing Activities
- -142.29
- Cashfrom Financing Activities
- -45.79
- Net Changein Cash
- -10.41
- Period
- 2024-06-30
- Total Revenue
- 230.69
- Selling/ General/ Admin Expenses Total
- 45.62
- Depreciation/ Amortization
- 13.4
- Other Operating Expenses Total
- 14.46
- Total Operating Expense
- 164.16
- Operating Income
- 66.53
- Net Income Before Taxes
- 83.09
- Net Income
- 60.77
- Diluted Normalized EPS
- 2.39
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 252.93
- Selling/ General/ Admin Expenses Total
- 45.77
- Depreciation/ Amortization
- 17.41
- Other Operating Expenses Total
- 5.12
- Total Operating Expense
- 194.46
- Operating Income
- 58.47
- Net Income Before Taxes
- 70.85
- Net Income
- 53.37
- Diluted Normalized EPS
- 2.2
- Period
- 2024-03-31
- Total Assets
- 2254.09
- Total Liabilities
- 203.42
- Total Equity
- 2050.66
- Tangible Book Valueper Share Common Eq
- 78.12
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 358.48
- Cashfrom Investing Activities
- -362.25
- Cashfrom Financing Activities
- -13.8
- Net Changein Cash
- -17.57
- Period
- 2023-12-31
- Total Revenue
- 219.82
- Selling/ General/ Admin Expenses Total
- 32.83
- Depreciation/ Amortization
- 12.75
- Other Operating Expenses Total
- 14.42
- Total Operating Expense
- 167.43
- Operating Income
- 52.39
- Net Income Before Taxes
- 65.47
- Net Income
- 46.75
- Diluted Normalized EPS
- 1.84
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 231.05
- Selling/ General/ Admin Expenses Total
- 28.58
- Depreciation/ Amortization
- 11.89
- Other Operating Expenses Total
- 13.16
- Total Operating Expense
- 144.98
- Operating Income
- 86.07
- Net Income Before Taxes
- 105.41
- Net Income
- 79.56
- Diluted Normalized EPS
- 3.13
- Period
- 2023-09-30
- Total Assets
- 2119.77
- Total Liabilities
- 184.37
- Total Equity
- 1935.4
- Tangible Book Valueper Share Common Eq
- 73.59
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 252.31
- Cashfrom Investing Activities
- -237.89
- Cashfrom Financing Activities
- -21.64
- Net Changein Cash
- -7.23
- Period
- 2023-06-30
- Total Revenue
- 347.55
- Selling/ General/ Admin Expenses Total
- 28.74
- Depreciation/ Amortization
- 12.54
- Other Operating Expenses Total
- 16.21
- Total Operating Expense
- 193.13
- Operating Income
- 154.42
- Net Income Before Taxes
- 163.94
- Net Income
- 120.59
- Diluted Normalized EPS
- 4.74
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 369.36
- Selling/ General/ Admin Expenses Total
- 25.6
- Depreciation/ Amortization
- 11.96
- Other Operating Expenses Total
- 15.77
- Total Operating Expense
- 212.24
- Operating Income
- 157.12
- Net Income Before Taxes
- 166.21
- Net Income
- 123.97
- Diluted Normalized EPS
- 4.87
- Period
- 2023-03-31
- Total Assets
- 1965.74
- Total Liabilities
- 230.56
- Total Equity
- 1735.18
- Tangible Book Valueper Share Common Eq
- 65.72
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 450.91
- Cashfrom Investing Activities
- -194.84
- Cashfrom Financing Activities
- -235.83
- Net Changein Cash
- 20.24
- Period
- 2022-12-31
- Total Revenue
- 353.77
- Selling/ General/ Admin Expenses Total
- 29.68
- Depreciation/ Amortization
- 12.24
- Other Operating Expenses Total
- 18.13
- Total Operating Expense
- 219.32
- Operating Income
- 134.46
- Net Income Before Taxes
- 146.08
- Net Income
- 107.72
- Diluted Normalized EPS
- 4.23
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Suven Pharmaceuticals Technical
Moving Average
SMA
- 5 Day1003.56
- 10 Day1028.64
- 20 Day1053.73
- 50 Day1165.42
- 100 Day1198.02
- 300 Day1005.2
Suven Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Syngene International
- 738.75
- -8.25
- -1.1
- 960
- 608
- 29606.98
- JB Chemicals & Pharmaceuticals
- 1761.25
- 1.8
- 0.1
- 2029
- 1473.95
- 27333.68
- Suven Pharmaceuticals
- 1104
- 48.45
- 4.59
- 1359
- 586.1
- 28103.97
- Gland Pharma
- 1538.85
- 12.45
- 0.82
- 2220.95
- 1413.75
- 25346.48
- Wockhardt
- 1557.15
- 141.55
- 10
- 1580
- 421
- 23886.83
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Syngene International
- 58.59
- 7.15
- 14.56
- 16.22
- JB Chemicals & Pharmaceuticals
- 50.09
- 9.27
- 20.54
- 16.06
- Suven Pharmaceuticals
- 87.27
- 12.88
- 27.91
- 33.21
- Gland Pharma
- 32.13
- 2.84
- 14.89
- 22.92
- Wockhardt
- -
- 5.88
- -10.63
- -12.7
Suven Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 12-Feb-25
- Quarterly Results
- 12-Nov-24
- Quarterly Results
- 09-Aug-24
- Quarterly Results
- 30-May-24
- Audited Results
- 05-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 08-Aug-23
- Quarterly Results
- 25-May-23
- Audited Results
- 06-Feb-23
- Quarterly Results
- 08-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 19-Dec-24
- 21-Nov-24
- POM
- 28-Nov-24
- 28-Oct-24
- COM
- 09-Aug-24
- 15-Jul-24
- AGM
- 15-Feb-24
- 12-Jan-24
- POM
- 15-Dec-23
- 10-Nov-23
- AGM
- 14-Dec-23
- 13-Nov-23
- POM
- 18-Aug-22
- 09-May-22
- AGM
- 31-Aug-21
- 08-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 29-Aug-22
- 12-Sept-22
- 09-Sept-22
- 1
- 30-Aug-22
- 12-Sept-22
- 09-Sept-22
- 5
- 02-May-22
- 17-May-22
- 13-May-22
- 1
- 03-May-22
- 17-May-22
- 13-May-22
- 1
- 01-Feb-22
- 16-Feb-22
- 15-Feb-22
- 1
- 02-Feb-22
- 16-Feb-22
- 15-Feb-22
- 2
- 08-Jun-21
- 17-Aug-21
- 13-Aug-21
- 1
- 03-Feb-21
- 18-Feb-21
- 17-Feb-21
- 1